Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OPTH with free AI briefings, catalyst countdowns, and dilution alerts.

OPTH · Optimi Health Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13.1M Cash on Hand
30.2mo Cash Runway
Follow OPTH by email Get an email when OPTH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OPTH, unsubscribe in one click. Privacy

📣 What OPTH Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Inonotus Obliquus Whole Extract Mood Disturbance Early Phase 1 · NCT05252598 Withdrawn
Psilocybine Mood Disturbance Early Phase 1 · NCT05252598 Withdrawn

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OPTH holds $13.1M in cash and short-term investments and burns about $1.3M/quarter from operations, an estimated runway of 30.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OPTH files for a raise →

Get the full OPTH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OPTH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.